Abstract:Platelets contribute to several types of cancer through plenty of mechanisms. Upon activation, platelets release many molecules, including growth and angiogenic factors, lipids, and extracellular vesicles, and activate numerous cell-types, including vascular and immune cells, fibroblasts, and cancer cells. Hence, platelets are a crucial component of cell-cell communication. In particular, their interaction with cancer cells can enhance their malignancy and facilitate the invasion and colonization of distant or… Show more
“…This could be attributed to the nesting effect of PLT on tumor cells, and this key role made it a drug carrier for anti-cancer drugs. 30 The increased targeting ability is conducive to enhancing the killing ability to the tumor, 31 which has been verified in the later killing ability of PM encapsulated nanomaterials to tumor cells and the treatment of subcutaneous tumors in mice. Figure 4 ( A ) CLSM images of 4T1 cells incubated with HMMD and HMMD@PG for 1 h and 3 h. The cell nuclei were stained as blue by DAPI, red was the fluorescence of DOX.…”
“…This could be attributed to the nesting effect of PLT on tumor cells, and this key role made it a drug carrier for anti-cancer drugs. 30 The increased targeting ability is conducive to enhancing the killing ability to the tumor, 31 which has been verified in the later killing ability of PM encapsulated nanomaterials to tumor cells and the treatment of subcutaneous tumors in mice. Figure 4 ( A ) CLSM images of 4T1 cells incubated with HMMD and HMMD@PG for 1 h and 3 h. The cell nuclei were stained as blue by DAPI, red was the fluorescence of DOX.…”
“…Several lines of evidence support the role of platelets in the pathogenesis of several inflammatory-based diseases, including cancer [57]. In cocultures of human colon carcinoma HT29 cells and platelets, Dovizio and colleagues have reported that unstimulated platelets interact rapidly with tumor cells through the binding of platelet collagen receptors (in particular, GPVI) and tumor components such as tumor components galectin-3 [58].…”
Section: Gpvi Blockers In Tumor Metastasismentioning
Percutaneous transluminal coronary angioplasty (PTCA) with or without vascular stenting is commonly used to treat coronary heart disease. However, restenosis occurs in 30-50% of patients undergoing simple balloon angioplasty and in 10-30% of patients who receive an intravascular stent. Collagen exposure at the vascular damage site leads to platelet adhesion and aggregation mainly via the activation of glycoprotein (GP) VI (a primary platelet collagen receptor), which contributes to the generation of thromboxane (TX) A 2 . It is produced from arachidonic acid by the activity of cyclooxygenase (COX)-1. TXA 2 is a potent mediator of platelet aggregation, vasoconstriction, and vascular smooth muscle cells (VSMC) proliferation and migration. In patients undergoing PTCA, an early increase of the systemic biosynthesis of TXA 2 occurs and is largely suppressed by low-dose Aspirin, a selective inhibitor of platelet COX-1. Thus, platelet activation and enhanced TXA 2 biosynthesis in response to vascular damage and collagen exposure is an early event which may contribute to restenosis. In this review, we report and discuss the evidence obtained in vivo and in vitro that the blockage of the interaction of platelet GPVI with injured vascular components, using novel antiplatelet agents such as Revacept, represents a safe strategy to mitigate vascular restenosis. Revacept, a dimeric fusion protein of the extracellular domain of GPVI and the human Fc-fragment, inhibits collagen-mediated platelet adhesion and subsequent aggregation at the site of vascular injury. Finally, the possible utility of this pharmacological approach in the prevention of tumor metastasis is discussed.
“…Drug delivery systems using nanoparticles are being developed as an alternative therapeutic route for chemotherapeutic drug transport that can minimize the side effects of chemotherapy in cancer patients (146). Nanoparticles modified with P-selectintargeting agents contain the antiplatelet agent ticagrelor and the anti-inflammatory agent celecoxib.…”
The interplay between platelets and tumors has long been studied. It has been widely accepted that platelets could promote tumor metastasis. However, the precise interactions between platelets and tumor cells have not been thoroughly investigated. Although platelets may play complex roles in multiple steps of tumor development, most studies focus on the platelets in the circulation of tumor patients. Platelets in the primary tumor microenvironment, in addition to platelets in the circulation during tumor cell dissemination, have recently been studied. Their effects on tumor biology are gradually figured out. According to updated cancer hallmarks, we reviewed the biological effects of platelets on tumors, including regulating tumor proliferation and growth, promoting cancer invasion and metastasis, inducing vasculature, avoiding immune destruction, and mediating tumor metabolism and inflammation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
